Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

68.47 +0.30 (+0.44%)
Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
20 21 Next >
NASDAQ:INCY stands out as a growth opportunity that won't break the bank.
For those who appreciate growth without the sticker shock, INCYTE CORP (NASDAQ:INCY) is worth considering. 
Via Chartmill
Exit Now! 3 Biotech Stocks to Sell in February 2024
These biotech stocks to sell represent incredibly risky bets, amidst the sector's volatility and looming economic unpredictability. 
Via InvestorPlace
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
The Analyst Verdict: Incyte In The Eyes Of 8 Experts
Via Benzinga
Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities
From Incyte
Via Business Wire
NASDAQ:INCY is not too expensive for the growth it is showing.
INCYTE CORP (NASDAQ:INCY) is not too expensive for the growth it is showing. 
Via Chartmill
Expert Ratings for Incyte
Via Benzinga
What's Up With Incyte Stock Lately?
Incyte Corporation (NASDAQ: INCY) shares are trading higher on Tuesday. The stock has risen rapidly since Monday. 
Via Benzinga
Earnings Scheduled For February 13, 2024
Companies Reporting Before The Bell • LCI Indus (NYSE:LCII) is likely to report quarterly earnings at $0.18 per share on revenue of $838.27 million. 
Via Benzinga
Despite its impressive fundamentals, NASDAQ:INCY remains undervalued.
INCYTE CORP (NASDAQ:INCY) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
Via Chartmill
Pancreatic Cancer Treatments Poised for Major Advances in 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:INCY),(NASDAQ:TNGX),(NASDAQ:RYZB),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
Novartis Agrees To Acquire German Blood Cancer-Drug Developer MorphoSys For €2.7B
Novartis' €2.7 billion public takeover offer for MorphoSys, unlocking a promising oncology pipeline with pelabresib and tulmimetostat. 
Via Benzinga
Biotech Stock MorphoSys Catapults 56% As Novartis Agrees To Buy It For $2.9 Billion
Novartis will add to its cancer treatment pipeline with via the German biotech. 
Via Investor's Business Daily
Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi®)
From Incyte
Via Business Wire
Why Is MorphoSys (MOR) Stock Up 50% Today?
News of a potential takeout bid for any company usually leads to a big surge. That's what investors are seeing today with MOR stock. 
Via InvestorPlace
MorphoSys Stock Soars After Report Says Novartis To Acquire Cancer-Drug Developer
Novartis is in advanced talks to acquire MorphoSys and appears to be beating out Incyte Corporation which has also made an offer to acquire MorphoSys. MorphoSys produces a lymphoma drug, Monjuvi, sold... 
Via Benzinga
5 top healthcare stocks for earnings growth in 2024
2024 holds promise for healthcare stocks, with Humana, Elevance, and others expected to boost earnings, as analysts say many industry pressures have been removed. 
Via MarketBeat
Incyte to Report Fourth Quarter and Year-End 2023 Financial Results
From Incyte
Via Business Wire
NASDAQ:INCY is probably undervalued for the fundamentals it is displaying.
For those who appreciate value investing, INCYTE CORP (NASDAQ:INCY) is a compelling option with its solid fundamentals. 
Via Chartmill
3 Pharma Stocks Could Be the Pills Your Portfolio Needs
These large-cap pharma stocks offer growth and value with existing medicines, deep pipelines and reasonable valuations. 
Via InvestorPlace
Analyst Highlights Aclaris Therapeutics' Encouraging Efficacy For Eczema Candidate, But Cautions On Data Variations
Wednesday, Aclaris Therapeutics Inc (NASDAQ: ACRS) released topline results from its Phase 2b study of ATI-1777, an investigational topical "soft" JAK 1/3 inhibitor, in patients with mild to  
Via Benzinga
In the world of growth stocks, NASDAQ:INCY shines as a value proposition.
Investors seeking growth at a reasonable cost should explore INCYTE CORP (NASDAQ:INCY). 
Via Chartmill
Incyte Highlights Growth Opportunities and Provides Business Updates at the 42nd Annual J.P. Morgan Healthcare Conference
From Incyte
Via Business Wire
For those who appreciate value investing, NASDAQ:INCY is a compelling option with its solid fundamentals.
In a market where value is scarce, INCYTE CORP (NASDAQ:INCY) offers a refreshing opportunity with its solid fundamentals. 
Via Chartmill
NASDAQ:INCY is showing decent growth, but is still valued reasonably.
For those who appreciate growth without the sticker shock, INCYTE CORP (NASDAQ:INCY) is worth considering. 
Via Chartmill
AI Meets Biotech: 3 Top Stocks Transforming Medical Science
The AI revolution is bringing big gains to biotechnology, including drugs, antibodies, and synthetic biology. 
Via InvestorPlace
Topics Artificial Intelligence
The 3 Most Undervalued Biotech Stocks to Buy in December
Biotech is an increasing area of interest in the financial markets, line your portfolio up with these winning biotech stocks. 
Via InvestorPlace
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease
From Incyte and Syndax Pharmaceuticals
Via Business Wire
S&P 500's Hidden Gems: 27 Stocks With 30%+ Upside Potential According To Wall Street Analysts Targets
Fifty-six percent of S&P 500 companies have shown positive performance in 2023 and 44% retreated Moderna Inc. (NASDAQ: MRNA) offers the highest upside potential (58%). 
Via Benzinga
Topics Stocks
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS